Abrysvo and Beyfortus Could Transform RSV Prophylaxis for Young Children in the US

Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo (RSVpreF) has received FDA approval for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth up to six months of age by active immunisation of pregnant individuals at 32–36 weeks gestation.